Acta Pharmaceutica Sinica B · 2016 · 82 citations · 30 references
PharmacyPharmaceuticsPharmacologyDrug DeliveryIntracellular TransportTargeted Drug DeliveryBlood-brain Barrier DeliveryBlood-brain Barrier PenetrationBrain Targeted DeliveryCell-penetrating PeptidesNasal Drug DeliveryProtein DeliveryBlood - Brain Barrier UptakeBlood-brain Barrier PermeabilityIntranasal AdministrationIntranasal ApproachIntranasal FormulationsIntranasal RetentionProtein Delivery Across Biological BarriersSmall Molecule Brain Targeting
Brain delivery of macromolecular therapeutics (e.g., proteins) remains an unsolved problem because of the formidable blood-brain barrier (BBB). Although a direct pathway of nose-to-brain transfer provides an answer to circumventing the BBB and has already been intensively investigated for brain delivery of small drugs, new challenges arise for intranasal delivery of proteins because of their larger size and hydrophilicity. In order to overcome the barriers and take advantage of available pathways (e.g., epithelial tight junctions, uptake by olfactory neurons, transport into brain tissues, and intra-brain diffusion), a low molecular weight protamine (LMWP) cell-penetrating peptide was utilized to facilitate nose-to-brain transport. Cell-penetrating peptides (CPP) have been widely used to mediate macromolecular delivery through many kinds of biobarriers. Our results show that conjugates of LMWP-proteins are able to effectively penetrate into the brain after intranasal administration. The CPP-based intranasal method highlights a promising solution for protein therapy of brain diseases.
30
In Vivo Protein Transduction: Delivery of a Biologically Active Protein into the Mouse
Steven R. Schwarze, Alan L. Ho, Adamina Vocero-Akbani et al. · Science · 1999 · 2.4K citations
Intravenous TAT-GDNF Is Protective After Focal Cerebral Ischemia in Mice
Gunnar P.H. Dietz, Mathias Bähr · Stroke · 2003 · 165 citations · Full text